An innovative humanized anti‐CTLA‐4 variant, designed to be more compact and optimized for Fc‐mediated antibody‐dependent cellular cytotoxicity (ADCC), has demonstrated enhanced tumor penetration and a more potent tumor immune response in comparison to conventional anti‐CTLA‐4 therapies.36 Here, CTLA4 is linked to neoplasm.